Podcasts

OncLive On AirTM is a podcast from OncLive® that provides oncology professionals with the resources and information they need to provide the best patient care. Segments cover every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. New episodes with exclusive interviews with leading oncology experts are released on Mondays and Thursdays.

Treatment of Advanced HER2-Positive Breast Cancer

May 27th 2021

Dr Jhaveri and colleagues highlight key clinical trials in the setting of advanced HER2-positive breast cancer and discuss the practical considerations of these data.

Treatment of Early-Stage HER2-Positive Breast Cancer

May 27th 2021

Dr Jhaveri and colleagues take an in-depth look at data from select clinical trials in the neoadjuvant and adjuvant settings for patients with HER2-positive breast cancer.

Unmet Needs in the Treatment of HER2-Positive Breast Cancer

May 27th 2021

In the first segment, Dr Jhaveri and colleagues discuss the unmet needs clinicians face in the treatment of patients with HER2-positive breast cancer.

Treatment of Metastatic HER2-Positive Breast Cancer

May 26th 2021

Dr Kaklamani and colleagues highlight key clinical trials such as DESTINY-Breast01, HER2CLIMB, NALA, and SOPHIA in the setting of advanced HER2-positive breast cancer and discuss the practical considerations of these data.

Neoadjuvant and Adjuvant Treatment of HER2-Positive Breast Cancer

May 26th 2021

Dr Kaklamani and colleagues take an in-depth look at data from select clinical trials in the neoadjuvant and adjuvant settings for patients with HER2-positive breast cancer.

Remaining Unmet Needs in the Treatment of HER2-Positive Breast Cancer

May 26th 2021

In the first segment, Dr Kaklamani and colleagues discuss the remaining unmet needs clinicians face despite recent advances in the treatment of patients with HER2-positive breast cancer.

Kaklamani Speaks to a Shifting HER2+ Breast Cancer Paradigm

May 24th 2021

Dr. Kaklamani discusses current treatment sequencing approaches in HER2-positive breast cancer and the benefits and challenges of moving effective treatments in earlier lines of therapy.

UCSD Faculty Contextualize Cases of Cutaneous Squamous Cell Carcinoma

May 20th 2021

Drs Park, Daniels, Sanghvi, and Kolb, discuss two high-risk non-melanoma skin cancer cases and highlighted patient and tumor risk factors to consider in the clinical setting.

Grivas and Wright Weigh In on the Benefits of Multidisciplinary Care in Bladder Cancer

May 17th 2021

Drs Grivas and Wright discussed the goals of the Seattle Cancer Care Alliance Bladder Cancer Multidisciplinary Clinic, data that support the use of a multidisciplinary approach in bladder cancer, and the lingering effects of the COVID-19 pandemic on collaboration across health care specialties.

O'Dea Offers Insight Into the Integration of Trastuzumab Deruxtecan in HER2+ Breast Cancer

May 13th 2021

Dr. O’Dea discusses the efficacy and safety of trastuzumab deruxtecan in patients with HER2-positive breast cancer, treatment sequencing recommendations, and future research directions for antibody-drug conjugates in the field.

Federico Outlines Needs, Nuances, and Necessities in Neuroblastoma Treatment

May 10th 2021

Sara M. Federico, MD, discusses the diagnosis and presentation of neuroblastoma, the role of multidisciplinary care, and novel therapies that could significantly affect the treatment paradigm for this malignancy.

FDA Approval Insights: Cemiplimab in Advanced PD-L1–High NSCLC and Advanced Basal Cell Carcinoma

May 6th 2021

Dr. Sezar and Dr. Stratigos discuss the FDA approvals of cemiplimab-rwlc in advanced non–small cell lung cancer and advanced basal cell carcinoma.

FDA Approval Insights: Liso-Cel in Refractory Large B-Cell Lymphoma

May 3rd 2021

Dr. Abramson discusses the significance of the FDA approval of lisocabtagene maraleucel in refractory large B-cell lymphoma and provided insight into the efficacy and safety profiles of the CAR T-cell therapy as reported in the TRANSCEND NHL 001 trial.

Riedel and Van Tine Spotlight Sarcoma Advances and Preview Ongoing Studies

April 29th 2021

Dr. Riedel and Dr. Van Tine discuss the multidisciplinary management of patients with sarcoma, the clinical impact of the FDA approval of ripretinib in the gastrointestinal stromal tumor paradigm, and other exciting advances in sarcoma.

FDA Approval Insights: TheraSphere Y-90 Glass Microspheres in HCC

April 26th 2021

Riad Salem, MD, discusses the unique elements of the TheraSphere, the data that supported the regulatory approval, and the anticipated future for the radioembolization technology in hepatocellular carcinoma.

Pagel Unpacks the Utility of PI3K Inhibitors in Lymphoid Malignancies

April 22nd 2021

Dr. Pagel discusses the advances that have been made with PI3K inhibitors in lymphoid malignancies, the impact of the FDA approval of umbralisib on the treatment paradigm in follicular lymphoma and marginal zone lymphoma, and ongoing research poised to expand the armamentarium.

Saba Spotlights the Nuances of Treating Nasopharyngeal Cancer

April 19th 2021

Dr. Saba shares the ins and outs of nasopharyngeal carcinoma, ongoing clinical trials, and the complexities of managing the rare disease.

Research Reflections: Sonpavde on Urothelial Cancer Updates From the 2021 GU Cancers Symposium

April 15th 2021

Dr. Sonpavde discusses key data presented during the 2021 Genitourinary Cancers Symposium in urothelial carcinoma and anticipated research directions with immunotherapy, chemotherapy, and antibody-drug conjugates.

FDA Approval Insights: Umbralisib in Marginal Zone Lymphoma and Follicular Lymphoma

April 12th 2021

Dr. Fowler discusses the data that served as the basis for the accelerated approval of umbralisib in marginal zone lymphoma and follicular lymphoma, the implications of the regulatory decision on clinical practice, and potential next steps for the PI3Kδ and CK1ε inhibitor.

FDA Approval Insights: Trilaciclib in Extensive-Stage Small Cell Lung Cancer

April 8th 2021

Dr. Weiss discusses the significance of the FDA approval of trilaciclib in extensive-stage small cell lung cancer and key efficacy and safety data that have been reported with the CDK4/6 inhibitor.